Alembic Pharmaceuticals secures tentative FDA nod for prostate cancer drug
NewsBytes | May 14, 2026 6:39 PM CST
Darolutamide a generic of Bayer's Nubeqa
Darolutamide is basically a generic version of Bayer's Nubeqa, which has an estimated market size of $3.16 billion for the 12 months ending March 2026.
Just last month, Alembic also secured final approval for fingolimod capsules (used for multiple sclerosis), adding another win to its lineup.
Despite this month's gains, though, Alembic's stock is still down 14% over the past year, so it's been a bit of a rollercoaster for investors.
READ NEXT
-
A cascade of problems in Adkabail near the highway
-
Understanding Pulmonary Embolism: Risks and Prevention
-
Karnataka: OMCs assure adequate fuel stocks, urge public to avoid panic buying
-
Tories urged to deal with Reform in Makerfield by-election: 'Stand aside!'
-
'No need to preach to Udupi people': Yashpal Suvarna attacks Lakshmi Hebbalkar
